This trial tests combining drugs and radiation to stop cancer from spreading.
- Endometrial Cancer
- Unresectable Endometrial Cancer
2 Primary · 2 Secondary · Reporting Duration: Up to 1 year
1 Treatment Group
Lenvatinib, Pembrolizumab and Hypofractionated (Hypofx) External Beam Radiation ...
1 of 1
18 Total Participants · 1 Treatment Group
Primary Treatment: Lenvatinib, Pembrolizumab and Hypofractionated (Hypofx) External Beam Radiation Therapy (EBRT) Group · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Female Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the government sanctioned Lenvatinib, Pembrolizumab and Hypofx EBRT as a feasible medical treatment?
"Due to the limited amount of data confirming efficacy and safety, our team has judged Lenvatinib, Pembrolizumab and Hypofractionated (Hypofx) External Beam Radiation Therapy (EBRT) Group on a 1-3 scale as a 1." - Anonymous Online Contributor
Are there still enrollees being incorporated into this research project?
"Clinicaltrials.gov data indicates that this medical study, which was initially posted on February 1st 2023, is not currently seeking patients. Unfortunately, enrolment for the trial has been suspended; however 3467 other trials are still actively recruiting individuals." - Anonymous Online Contributor